Fair Isaac R&D increased by 8.0% to $53.92M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.7%, from $45.04M to $53.92M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 2.4% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $45.83M | $41.14M | $38.98M | $36.39M | $35.88M | $35.51M | $36.63M | $40.27M | $41.46M | $41.60M | $42.64M | $40.88M | $44.22M | $44.21M | $45.15M | $45.04M | $47.21M | $50.95M | $49.91M | $53.92M |
| QoQ Change | — | -10.2% | -5.3% | -6.7% | -1.4% | -1.0% | +3.2% | +9.9% | +3.0% | +0.3% | +2.5% | -4.1% | +8.2% | -0.0% | +2.1% | -0.2% | +4.8% | +7.9% | -2.0% | +8.0% |
| YoY Change | — | — | — | — | -21.7% | -13.7% | -6.0% | +10.7% | +15.5% | +17.1% | +16.4% | +1.5% | +6.7% | +6.3% | +5.9% | +10.2% | +6.8% | +15.3% | +10.6% | +19.7% |